Fulgent Genetics, Inc. (BMV:FLGT)

Market Cap	15.35B
Revenue (ttm)	5.79B
Net Income (ttm)	-788.40M
Shares Out	n/a
EPS (ttm)	-25.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	421
Average Volume	1,270
Open	492.50
Previous Close	450.00
Day's Range	492.50 - 492.50
52-Week Range	315.00 - 492.50
Beta	n/a
RSI	55.49
Earnings Date	Feb 27, 2026

About Fulgent Genetics

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he...

• Industry: Medical Laboratories
• Founded: 2011
• Employees: 1,313
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: FLGT

Financial Performance

In 2024, Fulgent Genetics's revenue was $283.47 million, a decrease of -1.99% compared to the previous year's $289.21 million. Losses were -$42.71 million, -74.55% less than in 2023.

Financial numbers in USD